ECSP12011907A - Composiciones para tratar naúsea y vómito centralmente mediados - Google Patents
Composiciones para tratar naúsea y vómito centralmente mediadosInfo
- Publication number
- ECSP12011907A ECSP12011907A ECSP12011907A ECSP12011907A EC SP12011907 A ECSP12011907 A EC SP12011907A EC SP12011907 A ECSP12011907 A EC SP12011907A EC SP12011907 A ECSP12011907 A EC SP12011907A
- Authority
- EC
- Ecuador
- Prior art keywords
- vomiting
- treat
- compositions
- nause
- centrally
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Paints Or Removers (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26247009P | 2009-11-18 | 2009-11-18 | |
| US38270910P | 2010-09-14 | 2010-09-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP12011907A true ECSP12011907A (es) | 2012-10-30 |
Family
ID=43608757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP12011907 ECSP12011907A (es) | 2009-11-18 | 2012-05-17 | Composiciones para tratar naúsea y vómito centralmente mediados |
Country Status (40)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2722045B1 (en) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
| PE20121483A1 (es) | 2009-11-18 | 2012-12-02 | Helsinn Healthcare Sa | Composiciones para tratar nausea y vomito centralmente mediados |
| WO2013004766A1 (en) * | 2011-07-04 | 2013-01-10 | Ferrari Giulio | Nk-1 receptor antagonists for treating corneal neovascularisation |
| WO2013057554A2 (en) * | 2011-10-18 | 2013-04-25 | Helsinn Healthcare Sa | Therapeutic combinations of netupitant and palonosetron |
| US9403772B2 (en) | 2011-11-29 | 2016-08-02 | Helsinn Healthcare Sa | 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator |
| US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| CN103520725B (zh) * | 2012-07-05 | 2017-10-24 | 海思科医药集团股份有限公司 | 一种治疗呕吐的药物组合物 |
| RU2770050C2 (ru) | 2015-03-04 | 2022-04-14 | Ванда Фармасьютиклз Инк. | Способ лечения с применением традипитанта |
| CN106902086B (zh) * | 2015-12-23 | 2020-10-20 | 江苏恒瑞医药股份有限公司 | 一种包含奈妥匹坦的固体组合物 |
| GB201618425D0 (en) * | 2016-11-01 | 2016-12-14 | Acacia Pharma Ltd | method |
| GB201702250D0 (en) | 2017-02-10 | 2017-03-29 | Acacia Pharma Ltd | Method |
| CN108721214B (zh) * | 2017-04-14 | 2020-06-16 | 和龙 | 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途 |
| CN108853010A (zh) * | 2017-05-15 | 2018-11-23 | 和龙 | 奈妥吡坦环糊精包合物、复方组合制剂及其制备方法和用途 |
| CN109200018A (zh) * | 2017-07-04 | 2019-01-15 | 南京诺瑞特医药科技有限公司 | 含有奈妥吡坦的微乳制剂 |
| DK3710000T3 (da) * | 2017-11-17 | 2025-06-16 | Vanda Pharmaceuticals Inc | Tradipitant til anvendelse til behandling af gastroparese |
| WO2019148247A1 (en) * | 2018-02-02 | 2019-08-08 | Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) | Oral formulations and uses thereof |
| JP2024501994A (ja) * | 2020-12-25 | 2024-01-17 | 上海盛迪医▲葯▼有限公司 | Ｎｋ１拮抗剤プロドラッグ化合物と５－ｈｔ３受容体拮抗剤との併用使用 |
| EP4385500B1 (en) | 2022-12-12 | 2026-07-01 | Alfred E. Tiefenbacher (GmbH & Co. KG) | FIXED-DOSE COMBINATION INCLUDING NETUPITANT AND PALONOSETRON |
| AU2023393578A1 (en) | 2022-12-12 | 2025-07-03 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Fixed dose combination comprising netupitant and palonosetron |
| EP4385497A1 (en) | 2022-12-12 | 2024-06-19 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Antioxidant-free fixed dose combination of netupitant and palonosetron |
| EP4633608A1 (en) * | 2022-12-12 | 2025-10-22 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Antioxidant-free fixed dose combination of netupitant and palonosetron |
| WO2025246530A1 (en) * | 2024-05-30 | 2025-12-04 | The Chinese University Of Hong Kong | Personalized anti-emetic treatment for chemotherapy-induced nausea and vomiting |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU642178B2 (en) | 1989-11-28 | 1993-10-14 | Roche Palo Alto Llc | New tricyclic compounds |
| US5510486A (en) | 1994-07-26 | 1996-04-23 | Syntex (U.S.A.) Inc. | Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one |
| US6297395B1 (en) | 1995-11-10 | 2001-10-02 | The Secretary Of State For Defence In Her Brittanic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland | Calixarenes and their use for sequestration of metals |
| EP1035115B1 (en) | 1999-02-24 | 2004-09-29 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
| PT1303490E (pt) | 2000-07-14 | 2008-09-04 | Hoffmann La Roche | Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina |
| DK1349541T3 (da) | 2000-12-14 | 2007-01-08 | Hoffmann La Roche | Selvemulgerende lipidmatrix (SELM) |
| JP5690461B2 (ja) | 2002-11-15 | 2015-03-25 | ヘルシン ヘルスケア ソシエテ アノニム | 化学療法誘導嘔吐を治療するためのパロノセトロン |
| JO2735B1 (en) | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formulations of palonosetron |
| TWI355936B (en) | 2003-02-18 | 2012-01-11 | Helsinn Healthcare Sa | Uses of palonosetron hydrochloride |
| JP2006522817A (ja) * | 2003-04-08 | 2006-10-05 | プロジェニックス ファーマシューティカルズ，インコーポレーテッド | 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用 |
| CA2598762A1 (en) | 2005-02-25 | 2006-08-31 | F. Hoffmann-La Roche Ag | Tablets with improved drug substance dispersibility |
| US7479312B2 (en) | 2005-07-07 | 2009-01-20 | Konica Minolta Opto, Inc. | Retardation film, polarizing plate, and liquid crystal display device |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| AU2007219236B2 (en) * | 2006-02-23 | 2012-06-21 | Pfizer Limited | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines |
| EA016455B1 (ru) * | 2006-10-24 | 2012-05-30 | Хелсинн Хелткэр С.А. | Мягкие капсулы, содержащие палоносетрона гидрохлорид, имеющие улучшенную стабильность и биологическую доступность |
| US20110014117A1 (en) * | 2007-06-28 | 2011-01-20 | Schering Corporation | Anti-igf1r |
| EP2247757A2 (en) * | 2007-12-18 | 2010-11-10 | Schering Corporation | Biomarkers for sensitivity to anti-igf1r therapy |
| PE20121483A1 (es) | 2009-11-18 | 2012-12-02 | Helsinn Healthcare Sa | Composiciones para tratar nausea y vomito centralmente mediados |
-
2010
- 2010-11-18 PE PE2012000686A patent/PE20121483A1/es active IP Right Grant
- 2010-11-18 SI SI201031291T patent/SI2722045T1/sl unknown
- 2010-11-18 WO PCT/IB2010/003106 patent/WO2011061622A1/en not_active Ceased
- 2010-11-18 CN CN201610795817.1A patent/CN107050455B/zh active Active
- 2010-11-18 CA CA2778301A patent/CA2778301C/en active Active
- 2010-11-18 CN CN201610797549.7A patent/CN106512010A/zh active Pending
- 2010-11-18 ES ES14151676.5T patent/ES2559475T3/es active Active
- 2010-11-18 ES ES10805301.8T patent/ES2494015T3/es active Active
- 2010-11-18 DK DK14151683.1T patent/DK2722045T3/en active
- 2010-11-18 RS RSP20140423 patent/RS53491B1/sr unknown
- 2010-11-18 MY MYPI2012002073A patent/MY159393A/en unknown
- 2010-11-18 SI SI201030688T patent/SI2361090T1/sl unknown
- 2010-11-18 DK DK10805301.8T patent/DK2361090T3/da active
- 2010-11-18 AU AU2010320598A patent/AU2010320598B2/en active Active
- 2010-11-18 EP EP14151678.1A patent/EP2722044B1/en active Active
- 2010-11-18 RS RS20160833A patent/RS55206B1/sr unknown
- 2010-11-18 KR KR1020127015676A patent/KR101615108B1/ko active Active
- 2010-11-18 EP EP14151676.5A patent/EP2727590B1/en active Active
- 2010-11-18 CN CN201510047631.3A patent/CN104856999A/zh active Pending
- 2010-11-18 PT PT141516831T patent/PT2722045T/pt unknown
- 2010-11-18 HU HUE14151683A patent/HUE029677T2/hu unknown
- 2010-11-18 EA EA201290356A patent/EA026815B1/ru active Protection Beyond IP Right Term
- 2010-11-18 EP EP10805301.8A patent/EP2361090B1/en active Active
- 2010-11-18 ES ES14151683.1T patent/ES2595077T3/es active Active
- 2010-11-18 NZ NZ599439A patent/NZ599439A/en unknown
- 2010-11-18 PT PT108053018T patent/PT2361090E/pt unknown
- 2010-11-18 CN CN201610795827.5A patent/CN106421793B/zh active Active
- 2010-11-18 PL PL14151678T patent/PL2722044T3/pl unknown
- 2010-11-18 BR BR112012011485-9A patent/BR112012011485B1/pt active IP Right Grant
- 2010-11-18 PL PL10805301T patent/PL2361090T3/pl unknown
- 2010-11-18 PH PH1/2012/500887A patent/PH12012500887A1/en unknown
- 2010-11-18 PL PL14151683T patent/PL2722045T3/pl unknown
- 2010-11-18 MX MX2012005347A patent/MX2012005347A/es active IP Right Grant
- 2010-11-18 CN CN201510046972.9A patent/CN104856998A/zh active Pending
- 2010-11-18 JP JP2012539433A patent/JP5890780B2/ja active Active
- 2010-11-18 CN CN2010800521070A patent/CN102655864A/zh active Pending
- 2010-11-18 GE GEAP201012752A patent/GEP20156226B/en unknown
- 2010-11-18 AP AP2012006278A patent/AP3083A/xx active
- 2010-11-18 ES ES14151678.1T patent/ES2623503T3/es active Active
- 2010-11-18 HR HRP20140759AT patent/HRP20140759T1/hr unknown
- 2010-11-18 LT LTEP14151683.1T patent/LT2722045T/lt unknown
-
2012
- 2012-04-13 TN TNP2012000170A patent/TN2012000170A1/en unknown
- 2012-04-26 CR CR20120216A patent/CR20120216A/es unknown
- 2012-05-03 IL IL219576A patent/IL219576A/en active IP Right Grant
- 2012-05-10 NI NI201200090A patent/NI201200090A/es unknown
- 2012-05-15 DO DO2012000138A patent/DOP2012000138A/es unknown
- 2012-05-16 CL CL2012001276A patent/CL2012001276A1/es unknown
- 2012-05-17 EC ECSP12011907 patent/ECSP12011907A/es unknown
- 2012-05-18 CO CO12082329A patent/CO6551693A2/es not_active Application Discontinuation
- 2012-05-18 GT GT201200156A patent/GT201200156A/es unknown
- 2012-05-18 CU CU2012000078A patent/CU24048B1/es active IP Right Grant
- 2012-06-11 MA MA34953A patent/MA33810B1/fr unknown
-
2014
- 2014-08-18 SM SM201400112T patent/SMT201400112B/xx unknown
-
2016
- 2016-02-24 HK HK16102109.6A patent/HK1214147A1/zh unknown
- 2016-02-24 HK HK16102110.3A patent/HK1214148A1/zh unknown
- 2016-10-05 CY CY20161100991T patent/CY1118062T1/el unknown
- 2016-10-05 HR HRP20161277TT patent/HRP20161277T1/hr unknown
-
2017
- 2017-03-14 HR HRP20170419TT patent/HRP20170419T1/hr unknown
-
2022
- 2022-12-16 US US18/082,737 patent/US12042494B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24048B1 (es) | Composiciones para tratar náusea y vómito centralmente mediados | |
| MX2019008428A (es) | Inhibidores de glucosilceramida sintasa. | |
| MX2020002867A (es) | Inhibidores de glucosilceramida sintasa. | |
| CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
| MX379016B (es) | Composiciones y metodos para tratar enfermedad de gaucher. | |
| ECSP099634A (es) | Derivados de piridazinona útiles como inhibidores de glucano sintasa | |
| DK2252322T3 (da) | Vaccinesammensætninger | |
| CR20110553A (es) | Terapia complementaria contra el cáncer | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| UY32546A (es) | Composiciones y metodos para tratar cancer | |
| MX389168B (es) | Procedimiento para preparar inhibidores de la glucosilceramida sintasa. | |
| MX359209B (es) | Terapia de combinacion de procaspasa para gliobastoma. | |
| DOP2013000131A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
| UA35391U (ru) | Способ лазерно-хирургического удаления олигоастроцитом полушарий большого мозга с медианным распространением | |
| CY1115471T1 (el) | Συνθεσεις για την αντιμετωπιση της ναυτιας και του εμετου κεντρικης προελευσης | |
| TH149036B (th) | การบำบัดรักษาแบบสารรวมซึ่งประกอบรวมด้วยตัวยับยั้ง sglt และตัวยับยั้ง dpp4 | |
| TN2013000368A1 (en) | Glucosylceramide synthase inhibitors | |
| CO6721062A2 (es) | Cmposiciones y métodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek | |
| ECSP13012736A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek |